20 26 CH I ME RI C T H ERA P EUT IC S C H IM ER I C TH ER AP EU T IC S . C OM CHIMERIC PI ONEE RS IN CEL L THERAPY CHM ASX: CH I ME RI C T H ERA P EUT IC S C H IM ER I C TH ER AP EU T IC S . C OM Certain statements contained in this presentation, including, without limitation, statements...
Investor Presentation
Filed with ASX · · 19 pages · English
Release
Chimeric Therapeutics Limited on 6ix
In the deck
Story so far
Earlier from Chimeric Therapeutics
- CHM CDH17 Phase 1 clinical trial update - New DL 3 data
- Appointment of Financial Adviser for Strategic Review
- CHM announces positive Phase 1/2 data at ASCO
- Minaris Delivers 100% Manufacturing and Release Success for Chimeric Therapeutics' CDH17 Autologous CAR‑T Program
- Consolidation/Split - CHM
Later from Chimeric Therapeutics
- Chimeric receives $1.62M advance on FY26 R&D tax incentive
- Quarterly Activities/Appendix 4C Cash Flow Report
- Application for quotation of securities - CHM
- Trading Halt
- CHM ceases enrolment in Phase 1 trial and Company update
Follow Chimeric Therapeutics into a list and get an email when it puts out news.
Follow Chimeric Therapeutics